The Trump administration announced deals on Thursday with pharmaceutical giants Novo Nordisk and Eli Lilly that would lower the cost of GLP-1 drugs for many Americans, including those on Medicare. The administration negotiated how much both the government and consumers would pay for the drugs, which are used to treat obesity and diabetes as well as other cardiometabolic conditions. As soon as the public-private partnership TrumpRx launches, patients using the service will pay roughly $350 for a month's supply of the injectable drugs, according to senior administration officials. That price is set to scale down to $250 over the next two years for people paying completely out-of-pocket with no insurance. Those using the daily pill versions of the drug, which yet to be approved by the U.S. Fo

See Full Page